Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)

Summary

This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH 900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD). MK-8777 or placebo will be administered in a crossover fashion for two 3-week treatment periods. The two 3-week treatment periods will be separated by a 2-week placebo washout period. The primary objective is to compare the efficacy of various doses of MK-8777 to that of placebo in the treatment of ADHD symptoms in adults.

Timeline

Start

2008-04-01

Primary completion

2009-03-02

Completion

2009-03-09

Outcome

Mixed primary results

registry p = 0.0147; Mean Difference (Net) -5.6996 (97.5% CI -10.911 to -0.4881) NCT00610441 ↗

registry p = 0.5910; Mean Difference (Net) 0.9926 (97.5% CI -3.2961 to 5.2814) NCT00610441 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-8777	Unknown	100 mg	—
Subject	MK-8777	Unknown	300 mg	—

Indications